[Click eStock] "Voronoi Reflects VRN10 Competitiveness in Corporate Value"

Yuanta Securities on the 21st set a target price of 160,000 KRW for Voronoi, reflecting the value of the HER2-targeted breast cancer treatment VRN10.

Researcher Hyunsoo Ha from Yuanta Securities explained, "VRN10 is expected to apply for clinical trials by the end of this year," adding, "Clinical trials will begin from the first quarter of next year."

He continued, "VRN10 showed a strong inhibitory effect on HER2 TK, including normal HER2, while its impact on EGFR TK was very low," and added, "In cell line-specific inhibition experiments, VRN10 demonstrated excellent growth inhibition effects at low doses in HER2-expressing cells."

He further emphasized, "In cell lines such as HaCaT and A431, the effect on inhibiting cell growth was low," stating, "VRN10 is expected to show high efficacy at very low concentrations in HER2 cell lines." He analyzed that "the efficacy of VRN10 is believed to be due to the formation of a covalent bond with HER2 TK, resulting in irreversible TK inhibition."

Researcher Ha noted, "The low risk of hepatotoxicity of VRN10 will be an advantage in selecting combination drugs during the development of combination therapies," and expressed expectations that "the target market for VRN10 will be the second-line or later market, where Tucatinib, a new breast cancer treatment, is positioned."

He explained, "Another potential market for VRN10 is expected to be in combination with HER2 ADC," adding, "It could expand the low-expression market through TKI combination therapy and reduce the administered dosage."